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Background: Mutations in PMM2 impair phosphomannomutase-2 activity and cause the most frequent congenital
disorder of glycosylation, PMM2-CDG. Mannose-1-phosphate, that is deficient in this disorder, is also implicated in
the biosynthesis of glycosylphosphatidyl inositol (GPI) anchors.
Objective: To evaluate whether GPI-anchor and GPI-anchored proteins are defective in PMM2-CDG patients.
Methods: The expression of GPI-anchor and seven GPI-anchored proteins was evaluated by flow cytometry in
different cell types from twelve PMM2-CDG patients. Additionally, neutrophil CD16 and plasma hepatic proteins
were studied by Western blot. Transferrin glycoforms were evaluated by HPLC.
Results: Patients and controls had similar surface expression of GPI-anchor and most GPI-anchored proteins.
Nevertheless, patients displayed a significantly diminished binding of two anti-CD16 antibodies (3G8 and KD1) to
neutrophils and also of anti-CD14 (61D3) to monocytes. Interestingly, CD16 immunostaining and asialotransferrin
levels significantly correlated with patients’ age. Analysis by flow cytometry of CD14 with MΦP9, and CD16
expression in neutrophils by Western blot using H-80 ruled out deficiencies of these antigens.
Conclusions: PMM2 mutations do not impair GPI-anchor or GPI-anchored protein expression. However, the
glycosylation anomalies caused by PMM2 mutations might affect the immunoreactivity of monoclonal antibodies
and lead to incorrect conclusions about the expression of different proteins, including GPI-anchored proteins.
Neutrophils and monocytes are sensitive to PMM2 mutations, leading to abnormal glycosylation in immune
receptors, which might potentially affect their affinity to their ligands, and contribute to infection. This study also
confirms less severe hypoglycosylation defects in older PMM2-CDG patients.
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Congenital disorders of glycosylation (CDG) are caused
by defective glycosylation of glycoproteins and glyco-
lipids. Up to date more than 70 CDG have been reported
[1-3]. These disorders show an extremely broad clinical
spectrum involving nearly all organs, with degrees of se-
verity that range from early death to very mildly affected
adults [4]. The number of inborn defects of glycosylation* Correspondence: javier.corral@carm.es
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distribution, and reproduction in any mediumis expected to further increase rapidly [1]. The most preva-
lent N-linked disorder, CDG-Ia, first reported in 1980, is
an autosomal recessive defect caused by deficient phos-
phomannomutase (PMM) activity [5] due to mutations in
PMM2 [6]. Thus, this disorder is now called PMM2-CDG
[7]. PMM2 catalyzes the conversion of mannose-6 phos-
phate to mannose-1-phosphate, an early step in the as-
sembly of the lipid-linked oligosaccharide (LLO) precursor
required for N-glycosylation (Figure 1). The most widely
used method to screen for N-glycan synthesis defects is
isoelectric focusing of serum transferrin (Tf), showing a
type 1 pattern in PMM2-CDG (increase of asialo- and
disialotransferrin) [8].Med Central Ltd. This is an open access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Biosynthetic pathways depending on mannose-1-phosphate: N-glycosylation, GPI-anchor biosynthesis, and O-mannosylation.
Mannose-1-phosphate is the product of the phosphomannomutase activity, encoded by the PMM2 gene. The steps involved in the synthesis of
the lipid-linked oligosaccharides required for the N-glycosylation of proteins, and glycosylphosphatidyl inositol required for the anchor of other
proteins are detailed. The genes involved in each step are indicated, and those with mutations associated with congenital disorders of
glycosylation are marked in red.
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phosphate, although with lower requirements than
N-glycosylation (nine mannose residues): glycosylpho-
sphatidyl inositol (GPI) anchor biosynthesis (three
mannose residues), and O-mannosylation synthesis (one
mannose) (Figure 1) [9]. PMM2-CDG patients have no
symptoms of α-dystroglycan hypomannosylation. How-
ever, the identification of mutations in the genes for the 3
subunits of dolichol-phosphate-mannose (DPM) synthase
in patients with N-glycosylation defects and muscular
dystrophy-dystroglycanopathy syndrome [10] prompt fur-
ther studies to address whether impaired phospho-
mannomutase activity might also affect other metabolic
pathways requiring dolichol phosphate-mannose, like O-
mannosylation. Moreover, as far as we know, there is no
study evaluating GPI-anchor and GPI-anchored protein
expression in PMM2-CDG patients. Since GPI-anchored
proteins are involved in multiple pathways, defects in
these proteins may contribute to the complex phenotype
of this disease. For example, the tendency towards throm-
bosis in patients with PMM2-CDG could be multifactorial,
and potentially (at least in part), due to deficiency of GPI-
anchored complement inhibitors on the surface ofcirculating erythrocytes and other cells [11]. In this con-
text, it has to be noted that two GPI-anchor synthesis de-
fects, paroxysmal nocturnal haemoglobinuria (PNH), and
PIGM-CDG (Figure 1), exhibit a high rate of occurrence
of severe thrombotic events due to complement-mediated
hemolysis resulting from the deficiency of complement
regulatory proteins, CD55 and CD59 [12,13].
This study aimed to evaluate the expression of GPI-
anchor and GPI-anchored proteins in different cell types
from PMM2-CDG patients.
Material and methods
PMM2-CDG patients and controls
Twelve PMM2-CDG patients from different European
countries were enrolled in this study. Venous blood was
collected into citrate-tubes and delivered within 24–48
hours by express courier at room temperature to
Murcia, Spain, where all further studies were done.
At least one healthy control subject was recruited for
each patient, and samples were drawn and shipped
under the same conditions as described above. A total of
25 healthy controls, including 5 children, were also en-
rolled in this study.
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the aim of this study, which was performed according to
the declaration of Helsinki, as amended in Edinburgh in
2000, and they gave written informed consent. This
study obtained approval from the Reina Sofia Hospital
Ethics Committee.
Analysis of abnormal glycoforms of hepatic proteins,
antithrombin levels and PMM2 molecular study
A complete diagnostic workup of PMM2-CDG patients
was performed by looking for protein N-glycosylation
defects in three different hepatic proteins: transferrin,
antithrombin, and α1-antitrypsin. Transferrin glycoforms
were evaluated by HPLC as previously described [14].
Briefly, plasma samples were iron saturated, lipid pre-
cipitated and filtrated. Glycoforms were separated by
HPLC, and detected at 470 nm. To assess for antithrom-
bin defects, we determined anti-FXa activity using a
chromogenic method, and the presence of abnormal
glycoforms in plasma was evaluated by Western blot
essentially as reported [15]. Hypoglycosylated forms of α1-
antitrypsin were detected by Western blot using a poly-
clonal antibody (Dako, Glostrup, Denmark). Molecular
analysis of all 8 exons and flanking regions of the PMM2
gene was performed as previously described [16].Table 1 Cell types and molecules evaluated by flow cytometr























MoAb: Monoclonal antibody.Flow cytometry analysis
Flow cytometry is the method of choice for identifying
cells deficient in GPI-anchor linked proteins. In this
study we followed the guidelines for the diagnosis and
monitoring of a disease caused by such a deficiency,
PNH, recently published by the International Clinical
Cytometry Society (ICCS) [17] and by the Spanish Soci-
ety of Haematology and Haemotherapy [18]. Briefly, for
red blood cells we performed a no lyse-no wash proced-
ure; for FLAER white blood cells were lysed-washed and
then stained, while for white blood cells a stain-then-lyse
procedure was used. For granulocyte evaluation we
analyzed the following combinations of monoclonal anti-
bodies (mAb): CD16-PE, CD45-PerCP, CD64-APC;
CD24-PE, CD45-PerCP, CD64-APC; CD55-PE, CD45-
PerCP, CD64-APC. For monocyte assessment we used
CD14-PE, CD45-PerCP, CD64-APC. For erythrocyte
evaluation we performed analysis of CD61-FITC, CD55-
PE; CD61-FITC, CD59-PE (Table 1). Additionally, FLAER
(fluorochrome-conjugated (Alexa 488) fluorescein-labelled
proaerolysin) which binds specifically to the GPI anchor
was used to analyze GPI-deficient myeloid and lymphoid
populations (together with CD45-PerCP and CD64-APC).
Briefly, 50,000-100,000 events were collected using a
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3G8 (PE) BD Pharmingen
–(Alexa 488) Pinewood Scientific
KD1 Culture supernatant
3G8 (PE) BD Pharmingen
3G8 (PE-Cy5) BD Pharmingen
1A10 (PE) Becton-Dickinson
ML5 (PE) BD Pharmingen
Kat4c Dako
HA58 (PE) BD Pharmingen
–(Alexa 488) Pinewood Scientific
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Gate software (Becton Dickinson) and CellQuest (Becton
Dickinson) to obtain the mean fluorescence intensity
(MFI) of stained cells (Additional file 1: Figure S1).Erythrocyte analysis
We evaluated potential qualitative rather than quantitative
defects on the erythrocyte GPI-linked complement inhibi-
tor, CD59, which might contribute to the thrombotic
phenotype of PMM2-CDG patients. For this purpose, we
assayed A) whether the red blood cells (RBCs) in patients
were lysed by complement when normal serum was acid-
ified by the acidified-serum lysis test (Ham test), and B) if
reduced ionic strength of serum by addition of an iso-
osmotic solution of sucrose could activate the classic com-
plement pathway, and complement-sensitive cells would
then be lysed by the sucrose test [19,20].Localization of epitopes recognized by anti-CD16 and
anti-CD14 antibodies
To analyze the epitope recognition by KD1 and 3G8 pair
of mAb on CD16 antigen, and by 61D3 and MФP9 mAb
on CD14 antigen binding, competition experiments were
performed. Briefly, whole blood cells from healthy donors
were incubated first with the unconjugated KD1 mAb,
washed and then stained with the second conjugated mAb
(3G8-PE-Cy5). We also performed CD14 immunostaining
by incubation of cells with FITC-conjugated 61D3, and
after a washing step, they were stained with PE con-
jugated MФP9- mAb. The fluorescence intensity was
analyzed by flow cytometry, and compared to that




P1 Spain 1 M Y64C, R141H
P2 Spain 14 M R141H, E93A
P3 Spain 6 F P113L, T118S+
P4 Spain 1 M E33X,V44A
P5 Spain 4 F P113L haploins
P6 Belgium 13 M F119L, R141H
P7 Belgium 1 M P113L, T237R
P8 Belgium 8 M D188G, V231M
P9 Belgium 35 F P113L, R141H
P10 Belgium 35 F P113L, R141H
P11 Portugal 18 M R141H, C241S
P12 Denmark 12 M F119L homozy
Control Pool - - - -
*Area of asialo- and disialo- transferrin HPLC peaks (% of total transferrin).
**AT: anti-FXa activity of antithrombin as % of the value observed in a pool of 100conjugated 3G8- PE-Cy5 or MФP9-PE mAb on neutro-
phils or monocytes, respectively [21].Neutrophil isolation and CD16 evaluation by Western blot
Neutrophil isolation and Western blot analysis were
done essentially as previously described [22]. Briefly,
after dextran sedimentation to remove red blood cells,
we performed a Ficoll-Hypaque sedimentation to separ-
ate mononuclear cells from neutrophils. The neutrophil
pellet was removed and a hypotonic lysis step was done to
eliminate the remaining erythrocytes. Neutrophils
(3.75×105) were lysed with 10x volume ice-cold lysis buffer
[10 mM TrisHCl, 0.5 mM DTT, 0.035% SDS, 1mM
EGTA, 50 mM sodium fluoride, 50 μM sodium
orthovanadate, 5 mM benzamidine and 20 mM phenyl-
methylsulphonyl fluoride (PMSF)], denaturized and loaded
in 8% SDS polyacrylamide gels. After separation by elec-
trophoresis, neutrophil proteins were transblotted to
PVDF membranes. CD16 steady-state level was evaluated
by Western blot using the H-80 polyclonal antibody
(Santa Cruz Biotechnology Inc, Dallas, Texas, USA). As
loading control, we evaluated the expression of tubulin by
Western blot and Ponceau Red staining of the membrane.Statistical analysis
%MFI values are described as mean ± SD. Study groups
were compared by Mann–Whitney U test. P-values <0.05
were considered statistically significant.
Correlations between both CD16 and asialotransferrin
values according to age were analyzed by linear regres-
sion using SPSS software. P-values <0.05 were consid-
ered statistically significant.teristics of PMM2-CDG patients
ations *Transferrin **AT Clinical severity
Asialo Disialo
11.0 45.8 46 Severe
10.0 32.8 35 Moderate
P184D 23.6 44.1 22 Severe
21.5 38.2 17 Severe
uficiency 13.5 33.9 53 Severe
6.0 30.1 43 Moderate
27.6 40.5 17 Moderate
9.4 36.1 42 Moderate
12.7 35.7 28 Mild
8.7 32.6 34 Mild
8.0 25.0 48 Mild
gous 11.9 39.1 28 Moderate
1.3 0.8 100 -
healthy blood donors.
Figure 2 Level of expression of glycosylphosphatidyl inositol
(GPI) anchored-proteins on different blood cells in PMM2-CDG
patients and control subjects. The study was done by flow
cytometry using proaerolysin variant (FLAER). Values are expressed as
% mean fluorescence intensity (MFI) vs that observed in controls.
PMN: Polymorphonuclear cells.
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The characteristics of the PMM2-CDG patients included
in this study are shown in Table 2.
GPI-anchor and GPI-anchored protein expression
We found that the level of FLAER binding to white blood
cells from patients was similar to that of healthyFigure 3 Expression of A) GPI-anchored proteins, and B) non GPI-anc
subjects. The study was done by flow cytometry using the monoclonal an
mean fluorescence intensity (MFI) vs that observed in controls. RBC: red bloindividuals (Figure 2). In agreement with this result, a
similar surface expression of most specific GPI-
anchored proteins was observed in PMM2-CDG pa-
tients and in controls on lymphocytes (CD48), erythro-
cytes (CD55, and CD59), monocytes (CD55) and
neutrophils (CD55, CD24 and CD66) (Figure 3A). A simi-
lar expression of non-GPI anchored proteins was also ob-
served in patients and in controls on lymphocytes (CD3,
CD19, and CD16), monocytes (CD33) and neutrophils
(CD54) (Figure 3B).
However, analysis of CD16 on granulocytes, performed
in parallel by two different laboratories (Centro Regional
de Hemodonación and Departamento de Bioquímica,
Biología Molecular B de Inmunología), revealed that
PMM2-CDG patients displayed a significantly dimin-
ished CD16 immunostaining using 3G8 mAb compared
to controls (Figure 4A). In contrast, the staining of
CD16 in lymphocytes, where this molecule exists as a
transmembrane non GPI-linked form, was similar in
PMM2-CDG patients and controls (Figure 3B). Two pa-
tients, P4 and P8, showed negligible binding of anti-
CD16 using two different mAb: 3G8 and KD1 (Table 3).
Interestingly, these two mAb seem to recognize different
but close epitopes since preincubation with KD1 clone
strongly reduced 3G8 staining of PMN cells (Additional
file 2: Figure S2A). The reduction of CD16 expression on
neutrophils seemed to be restricted to children with
PMM2-CDG, since the three available adult PMM2-CDG
patients displayed normal values (Figure 4A). To analyze
whether the decreased CD16 immunostaining was a realhored proteins on different blood cells in PMM2-CDG and control
tibodies indicated in Material and Methods. Values are expressed as %
od cells.
Figure 4 Expression of CD16 in neutrophils of PMM2-CDG patients
and control subjects. A) Flow cytometry analysis using 3G8 monoclonal
antibody in the whole cohort of patients and according to age. Values
are expressed as % mean fluorescence intensity (MFI) vs that observed in
controls. B)Western blot analysis using the H-80 polyclonal antibody. As
loading controls, we stained the membrane with Ponceau Red and
evaluated the expression of tubulin.
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the antibody, we performed Western blot analysis using a
polyclonal antibody (H-80) against neutrophils. This assay
revealed similar levels of CD16 in neutrophils in PMM2-
CDG and in controls (Figure 4B).
It is also worth to note that opposite results were ob-
served in CD14 staining on monocytes depending on theTable 3 Expression of surface proteins in P4 and P8
PMM2-CDG patients evaluated by flow cytometry
Neutrophils Lymphocytes
CD16 CD55 CD24 CD66 CD16
3G8 KD1 1A10 ML5 Kat4c 3G8
P4 5.3% 4.5% 125.7% 123.7% 71.6% 126.8%
P8 10.8% 6.4% 56.8% 57.3% ND 196.2%
Values are expressed as % mean fluorescence intensity vs that observed in
parallel controls.
ND: not determined.monoclonal antibody used in flow cytometry analysis.
MФP9 revealed similar staining of CD14 in PMM2-CDG
patients and in controls (p= 0.400) (Figure 5A). In con-
trast, 61D3 consistently identified a significant decrease in
CD14 binding on PMM2-CDG monocytes (p= 0.002)
(Figure 5A). These antibodies seem to recognize distant
epitopes since preincubation of monocytes with one anti-
CD14 antibody does not affect the staining ability of the
second one (Additional file 2: Figure S2). Contrary to what
was seen with the specific reduction in CD16 granulocyte
expression in children, the decrease of anti-CD14 61D3
binding to monocytes was observed both in children and
adults with PMM2-CDG (Figure 5B).
Erythrocyte lysis
The Ham’s acidified-serum and the sucrose tests were
negative in all PMM2-CDG patients, indicating no sig-
nificant qualitative defect on the erythrocyte surface
leading to increased sensitivity to cell lysis mediated by
complement (data not shown).
N-glycosylation analysis of hepatic proteins
All patients exhibited a characteristic HPLC pattern for
PMM2-CDG, with increased asialo- and disialotrans-
ferrin fractions (Table 2). Similarly, all patients had sig-
nificant antithrombin deficiency (Table 2) and increased
levels of abnormal glycoforms of antithrombin and α-
antitrypsin (Figure 6).
Discussion
Since mannose-1-phosphate is required for the synthesis
of both LLO and GPI-anchor, one would suspect that pa-
tients with congenital defects affecting enzymes involved
in the early and common steps of these pathways might
have defects in both the glycan content of N-glycoproteins
and the GPI-anchor/GPI-anchored protein expression
(Figure 1). Actually, GPI-anchored protein deficiencies are
included among the congenital disorders of glycosylation
[1,12,22-24]. However, as far as we know, no study has
evaluated any potential effect of congenital disorders of
glycosylation on GPI-anchor and GPI-anchored protein
expression. In this study we have addressed this issue in
the most prevalent CDG: PMM2-CDG. We have analyzed
a broad range of GPI-anchored proteins in four different
blood populations from 12 PMM2-CDG patients with dif-
ferent ages, gender, PMM2 mutations and clinical expres-
sion of disease. Our study suggests that in contrast to the
significant effect on N-glycosylation, mutations in PMM2
have negligible effects on GPI-anchor and GPI-anchored
protein expression in different blood cells. Several hypoth-
eses can be proposed to explain this observation: i, The
synthesis of GPI-anchors requires a smaller number
of mannoses (three) than the synthesis of LLO (nine)
(Figure 1). Thus, the residual PMM activity of PMM2-
Figure 5 Expression of CD14 in monocytes of PMM2-CDG patients and control subjects evaluated by flow cytometry. A) Results obtained with
MФp9 and 61D3 monoclonal antibodies in the whole cohort of patients. B) Expression of CD14 in monocytes according to age. The study was done
with the 61D3 monoclonal antibody. Values are expressed as % mean fluorescence intensity (MFI) vs that observed in controls. **p< 0.01; *p< 0.05.
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requirements for normal GPI-anchor synthesis. ii, It is pos-
sible that when GDP-Man and Dol-P-Man are in limited
supply, they are used more efficiently in other pathways, so
that GPI anchoring occurs but N-glycosylation is incom-
plete, as suggested by Thomas and coworkers [25]. iii, A
different turnover time of these mannosylated structures.
iv, Elements with the ability to modulate PMM2 defects by
different mechanisms (PMM1 by redundancy, or PGM
and PMI by affecting the balance of complementary path-
ways) might generate mannose-1-phosphate specifically
used in the GPI-anchor synthesis. Further studies are re-
quired to validate these hypotheses. Independently of this,
our study shows that neither the GPI-anchor nor the GPI-Figure 6 Glycoforms of antithrombin and α1-antitrypsin in plasma of
Normal glycoforms are indicated by solid arrows and hypoglycosylated glyanchored protein expressions are affected in PMM2-CDG
patients, with the restriction that we have not tested
whether the GPI-anchors of these patients are qualitatively
affected or show heterogeneity.
According to these results, quantitative defects of GPI-
anchor/GPI-anchored proteins are unlikely to be in-
volved in the multisystemic clinical expression of
PMM2-CDG patients. We were particularly interested to
investigate whether a potential CD59 defect in erythro-
cytes of PMM2-CDG patients might contribute to their
increased incidence of thrombosis [11,15,26]. This defect
is usually evaluated through the complement-mediated
lysis of erythrocytes, similar to patients with acquired
(PNH) or with congenital GPI deficiency (PIGM-CDG)one control, three adults, and three children with PMM2-CDG.
coforms by dashed arrows.
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CDG individuals observed by flow cytometry analysis, the
negative results observed in the Ham’s and sucrose tests,
and the absence of anemia in PMM2-CDG patients [4]
argue against quantitative and qualitative CD59 defects in
these patients. Therefore, in PMM2-CDG patients, mech-
anism(s) different from complement-mediated hemolysis,
seem to be involved in the disturbance of the hemostatic
system leading to increased risk of thrombosis. This may
be associated with the significant deficiencies of relevant
anticoagulant elements (antithrombin, protein C and pro-
tein S) although they also have deficiencies of procoagu-
lant factors (especially Factor IX and XI) associated with a
significant deficiency of relevant anticoagulant elements
(antithrombin, protein C and protein S) and procoagulant
factors (factor IX and XI) [28].
Additionally, CD16 and CD14 immunostaining of neu-
trophils and monocytes, respectively, was found to be sig-
nificantly reduced in PMM2-CDG patients by flow
cytometric analysis with 3G8 and KD1 (CD16) and 61D3
(CD14) monoclonal antibodies. CD16, the low affinity Fcγ
receptor III for IgG (FcγRIII) exists as a polypeptide-
anchored form (FcγRIIIA, or CD16-A) in human natural
killer cells and monocyte/macrophages, and as a GPI-
anchored form in human neutrophils (FcγRIIIB or CD16-
B) [29]. CD14 is a component of the innate immune
system that along with the Toll-like receptor 4 and MD-2,
acts as a co-receptor for the detection of bacterial lipo-
polysaccharide and also exists in two forms: either an-
chored into the membrane by a GPI tail (mCD14), or
present in a soluble form (sCD14) [30]. Reduced CD16 ex-
pression is likely to contribute to the impaired clearance
of immune complexes [31]. Moreover, a CD14 deficient
animal model exhibits higher bacterial disease severity
[32]. Consequently, the decreased CD16 and CD14 ex-
pression could potentially contribute to explain the recur-
rent infections described in PMM2-CDG patients [33,34].
However, several lines of evidences from our study suggest
that these patients express normal levels of CD16 andFigure 7 Correlations of CD16 binding to neutrophils (%mean fluores
to age in PMM2-CDG patients.CD14 in neutrophils and monocytes, respectively. The ap-
parent deficiency detected by 3G8, KD1, and 61D3 can be
explained by the ability of these antibodies to recognize an
epitope influenced by varying proportions of mannose
contents, resulting from the PMM2 mutations of these pa-
tients. Indeed, a previous study has shown that the immu-
noreactivity of the 3G8 epitope on CD16 expressed on
neutrophils is dependent primarily on a high mannose-
type oligosaccharide, according to the sensitivity to the
endo H digestion of the receptor [35], and KD1 may
recognize a very close epitope (Additional file 2: Figure
S2). Moreover, it has been shown that the FcγIII receptors
of natural killer cells and neutrophils differ in their affinity
to IgG because of primary sequence differences between
the two receptor isoforms, and also by cell type-specific
glycosylation of the receptor [36], which justifies the dif-
ferent CD16 expression on lymphocytes and neutrophils
of PMM2-CDG patients. Further studies must investigate
if the abnormal glycosylation of CD16 in neutrophils and
CD14 in monocytes of PMM2-CDG patients affects the
function of these immune receptors, as suggested for
CD16 [35], which might potentially be implicated in the
recurrent infections of these patients.
The reduced staining of CD16 on neutrophils (detected
by 3G8 or KD1 binding) was striking in children, but not
in the three adult PMM2-CDG patients analyzed. Interest-
ingly, significant correlations between both CD16 and
asialotransferrin with age were observed (Figure 7). These
results agree with the suggested stabilization of glycosyla-
tion defects with age described in a previous study [37],
and might explain the progressive normalization of the
transferrin profile in patients who initially present with an
abnormal pattern [38], although further studies including
serial analysis of additional patients comparing values at
different points in time should be performed to fully valid-
ate it. Indeed, age-related changes of glycoproteins cur-
rently represent an active research area [39]. It remains to
be determined whether these changes might also have
prognostic relevance in PMM2-CDG patients, as most ofcence intensity -MFI- vs controls) and asialotransferrin according
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clinical phenotype including recurrent infections, in the
first years of life and show a relatively steady clinical pic-
ture by puberty [40].
In conclusion, PMM2 mutations do not impair GPI-
anchor or GPI-anchored protein expression. However, the
glycosylation anomalies caused by PMM2 mutations
might affect the immunoreactivity of monoclonal anti-
bodies and thus lead to incorrect conclusions about
the expression of different proteins, including GPI-
anchored proteins. Our results also suggest that neutro-
phils and monocytes are sensitive to PMM2 mutations,
and relevant immunologic molecules could have abnor-
mal proportion of mannose content with potential func-
tional consequences that might contribute to explain
the recurrent infections of PMM2-CDG patients. Fi-
nally, our study confirms the stabilization of glycosyla-
tion defects with age.
Additional files
Additional file 1: Figure S1. Gating strategies used to define
granulocytes (blue), monocytes (green), and lymphocytes (red), by (A)
forward and side scatter characteristics, (B) immunostaining of CD45, and
to better define the monocytic cells, (C) by CD64 expression. Cells within
these gates were analyzed independently for expression of GPI and
non-GPI molecules by PE-labelled antibodies. The histogram (D)
represents CD16 expression in granulocytes from a PMM2-CDG patient
(blue) and a control subject (black). PE, phycoerythrin; PerCP, Peridinin
chlorophyll protein; APC, allophycocyanin.
Additional file 2: Figure S2. Epitope analysis of CD16 and CD14
antibodies. (A) Whole blood cells were either stained directly with
PE-Cy5-conjugated 3G8 anti-CD16 mAb (dark-unfilled histogram) or
preincubated with unlabelled KD1 anti-CD16 mAb, and then stained with
the fluorochrome labelled 3G8 anti-CD16 antibody (light-unfilled
histogram) and analyzed by flow cytometry. (B) Whole blood cells were
incubated either directly with MФp9 anti-CD14-PE (dark-unfilled
histogram) or preincubated first with 61D3 anti-CD14-FITC, and then
stained with MФP9 anti-CD14-PE (light-unfilled histogram). Dark-filled
histograms represent negative control cells treated with irrelevant
isotype-matched control antibody.
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